Please login to the form below
Ranbaxy
This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.
Nearly half of all clinical trials not published
Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35
Latest news
-
Lundbeck challenge to EC pay-for-delay ruling fails
The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.
-
India denies Vertex patent on cystic fibrosis drug Orkambi
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
-
Heart drug sales continue downward spiral
The Swiss firm has managed to delay some generic forms of its drug onto the market until last year, when Ranbaxy was granted approval to sell its copycat form of valsartan.
-
Takeda to pay $2.4bn to settle Actos cancer suits
Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.
-
Teva slapped with $512m fine on pay-for-delay deal
Ranbaxy Laboratories. ... Mylan and Ranbaxy, which are also defendants in the case, are not part of the settlement.
More from news
Approximately 6 fully matching, plus 92 partially matching documents found.
Latest Intelligence
-
Pharma deals in April 2015
The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy
-
Allergan and taking a specialised approach
But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and
-
Pharma deals during April 2014
for its stake in Ranbaxy in 2008, not to mention the 2013 $500m payment to the US authorities to settle 7 felony charges. ... is rumoured that a solution will be to replace the Ranbaxy brand with the Sun Pharma moniker at least in the US.
-
Deal Watch table for April 2014
Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.
-
Positive prospects for pharma in Latin America
Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Competition from within
Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,
-
Exploring MINT: Part 3 - Nigeria
as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Associate Director
-
£75, 000-90, 000
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
-
Medical Writer
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Business Director
-
Competitive Salary Offered
-
Account Director
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
Pegasus
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
